Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00006436 · OUTCOME

Percentage of Participants With Complete Response

EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection · Source last updated 2026-08-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
Not reported
Time frame
The participants were followed for an average of 6 months to determine response to therapy.

What was measured

Complete response was assessed by the Cheson Response Criteria. Complete response is disappearance of all signs and symptoms of lymphoma for a period of at least one month. All lymph nodes and nodal masses must have regressed to normal size (1.5 cm in their greatest transverse diameter for nodes \> 1.5 cm before therapy).

Analysis population: One participant declined to participate before treatment started, and one participant was not evaluable.

Groups in this outcome

Arm 1-Combination Chemo and Biological Therapy

Combination chemo and biological therapy Rituximab: 2 doses of rituximab every cycle: first dose on Day 1 and 2nd dose on Day 5 Filgrastim: Filgrastim day 6 until absolute neutrophil count (ANC) reaches 5000 after the nadir, every cycle Etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin hydrochloride (EPOCH): combination chemotherapy: EPOCH every 3 weeks for minimum of 3 cycles and max of 6 cycles

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm 1-Combination Chemo and Biological Therapy66

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm 1-Combination Chemo and Biological Therapy95Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        95
denoms
  1. counts
    1. group Id
      OG000
      value
      66
    units
    Participants
description
Complete response was assessed by the Cheson Response Criteria. Complete response is disappearance of all signs and symptoms of lymphoma for a period of at least one month. All lymph nodes and nodal masses must have regressed to normal size (1.5 cm in their greatest transverse diameter for nodes \> 1.5 cm before therapy).
groups
  1. description
    Combination chemo and biological therapy Rituximab: 2 doses of rituximab every cycle: first dose on Day 1 and 2nd dose on Day 5 Filgrastim: Filgrastim day 6 until absolute neutrophil count (ANC) reaches 5000 after the nadir, every cycle Etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin hydrochloride (EPOCH): combination chemotherapy: EPOCH every 3 weeks for minimum of 3 cycles and max of 6 cycles
    id
    OG000
    title
    Arm 1-Combination Chemo and Biological Therapy
param Type
NUMBER
population Description
One participant declined to participate before treatment started, and one participant was not evaluable.
reporting Status
POSTED
time Frame
The participants were followed for an average of 6 months to determine response to therapy.
title
Percentage of Participants With Complete Response
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice